New treatment for common incurable eye condition: Pterygium/pinguecula treatment results

Dipyridamole is a cardiovascular drug, used for the past 55 years for treating angina and preventing stroke. It also has wide applicability for eye disorders, having been researched for various eye ailments over the past four decades, including diabetic retinopathy, ocular hypertension and retinal hemorrhage. In 2014, MedInsight published the first case report of a pterygium patient being successfully treated with dipyridamole eye drops.

Pterygium, or Surfer's Eye, is a benign growth that affects 10% of the population worldwide. It is more prevalent with older age. An early-stage pterygium is known as a pinguecula, and affects 50% of the population. Besides being unsightly, pterygium and pinguecula often become inflamed and cause dry eye. Eventually, they can completely obstruct vision.

In the findings presented at ISVER in Kfar Maccabia, Israel, researchers analyzed outcomes of dry-eye symptoms reported by patients with pterygium. Using a well-accepted survey known as the Ocular Surface Disease Index, OSDI, the researchers found that there was a maximum reduction in OSDI scores averaging 52.4% during the course of treatment for 25 patients. Some patients reported a complete resolution of symptoms. Photographic evidence showed marked antiangiogenic effects and regression of the pterygia.

"These results are very exciting," said Moshe Rogosnitzky, director of the Center for Drug Repurposing at Ariel University, who discovered this novel treatment. "Until now, the only known treatment for pterygium has been surgical removal, which involves a high recurrence rate. In addition, patients are often given topical steroids to treat their symptoms, but this can result in glaucoma. Now we have a promising potential treatment for this very difficult to treat disorder, and it appears to be not only effective, but entails only a small amount of a very safe medicine. This treatment possibility offers very distinct advantages over the existing treatment offered."

Aaron Frenkel, research coordinator for MedInsight, added that studies are currently being planned at medical centers in Israel, Europe, Turkey and India. "This drug does not yet have commercial sponsorship, so studies are taking longer to initiate since research funds are dependent on donors. We are hopeful that clinical trials will begin later this year," said Frenkel.